


Pharmacokinetics



Predictable pharmacokinetics of telavancin support a once-daily IV dosing regimen¹

Mean (SD) concentrations in plasma following a 120 min IV administration of telavancin in healthy subjects¹




IV, intravenous; SD, standard deviation.

1. Shaw JP *et al.* *Antimicrob Agents Chemother* 2005; **49**: 195–201.

Telavancin has a linear pharmacokinetic profile¹

Dose linearity analysis for AUC for 120 min IV infusions of telavancin
1–12.5 mg/kg in healthy subjects¹



AUC, area under curve; IV, intravenous.

1. Shaw JP *et al.* *Antimicrob Agents Chemother* 2005; **49**: 195–201.

Accumulation of telavancin in plasma is minimal following multiple doses¹

Pharmacokinetic parameters for telavancin following daily IV infusions for 7 consecutive days in healthy subjects¹

Dose	C _{max} (µg/mL)	AUC (µg•h/mL)	T _{1/2} (h)	AUC Day 7/1
7.5 mg/kg				
Day 1	90.3	668	7.86	1.05
Day 7	96.7	700	8.83	
12.5 mg/kg				
Day 1	155	1013	7.26	1.02
Day 7	151	1033	9.11	
15 mg/kg				
Day 1	181	1239	7.33	1.01
Day 7	203	1165	8.78	


IV, intravenous; AUC, area under curve.

1. Shaw JP *et al.* *Antimicrob Agents Chemother* 2005; **49**: 195–201.

Telavancin penetrates well into pulmonary fluid and extensively into alveolar macrophages¹

- Telavancin remained above the telavancin MIC₉₀ value for MRSA over 24 hours¹

Steady-state concentrations of telavancin in the plasma, pulmonary epithelial lining fluid and alveolar macrophages of healthy subjects (n=20)¹




MIC₉₀, minimum inhibitory concentration that inhibited growth of 90% of the MRSA isolates; MRSA, methicillin-resistant *S. aureus*.

1. Gotfried MH *et al. Antimicrob Agents Chemother* 2008; **52**(1): 92–7.

Telavancin bactericidal activity *in vitro* against MRSA is unaffected by pulmonary surfactant¹

Change in minimum inhibitory concentration (MIC) for MRSA in the presence of lung surfactant¹



MRSA, methicillin-resistant *S. aureus*.

1. Gotfried MH *et al. Antimicrob Agents Chemother* 2008; **52**(1): 92–7.